Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer/Pharmacia Merger Review: Firms Expect Second-Request From FTC

Executive Summary

The Federal Trade Commission review of the Pfizer/Pharmacia merger should progress relatively smoothly because the same FTC reviewers worked with Pfizer on the Warner-Lambert deal, CEO Hank McKinnell told the Bear Stearns healthcare conference in New York City Sept. 17

You may also be interested in...

Pfizer’s Friendly Tack: McKinnell Shares Credit With Hassan, Offers No. 2 Spot

Pfizer's $60 bil. offer for Pharmacia could be a landmark event in the remaking of the Pfizer image, as well as a large-scale strategic move to broaden Pfizer's product line into new specialties and deepen the pipeline

Pfizer/Warner Pro Forma Accounting Shows 1.5% Margin Benefit From Lipitor

Pfizer/Warner-Lambert's pro forma operating margins will be 1.5 percentage points closer to the Pfizer level after the elimination of double-counting of Lipitor sales.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts